Indegene Limited IPO Allotment Status: Here’s How To Check Status And Latest GMP
The Rs 1,841.76 crores Indegene Limited IPO is a book-built issue. The offering comprises a fresh issue of 1.68 crore shares aggregating to Rs 760.00 crores and an offer for sale of 2.39 crore shares aggregating to Rs 1,081.76 crores.
Indegene IPO was open for subscription on May 6, 2024 and closed on May 8, 2024. The allotment for the Indegene IPO is expected to be finalised on Thursday, May 9, 2024. Indegene IPO will be listed on BSE and NSE with a tentative listing date fixed as Monday, May 13, 2024.
Indegene IPO price band is set at ₹430 to ₹452 per share. The minimum lot size for an application is 33 shares. The minimum amount of investment required by retail investors is ₹14,916. The minimum lot size investment for sNII is 14 lots (462 shares), amounting to ₹208,824, and for bNII, it is 68 lots (2,244 shares), amounting to ₹1,014,288.
Kotak Mahindra Capital Company Limited, Citigroup Global Markets India Private Limited, J.P. Morgan India Private Limited, and Nomura Financial Advisory And Securities (India) Pvt Ltd are the book running lead managers of the Indegene IPO, while Link Intime India Private Ltd is the registrar for the issue.
Here’s how you can check the allotment status of Indegene Limited IPO:
Step 1: Go to the BSE website.
Step 2: Choose ‘Equity’ and then the issue name from the selection menu.
Step 3: Enter your application number as well as your PAN card number and press ‘Search’.
You can also follow a similar procedure to check the allotment status on the Registrar’s website:
Step 1: Go to the Link InTime India Private Ltd website.
Step 2: Select the IPO name by clicking on ‘Company Selection’.
Step 3: Input your PAN, application number, DP/Client ID, or account number/IFSC number and click on ‘Search’.
If the details are input correctly, the status will appear only after allotment. The equity shares are expected to be credited to successful investors’ demat accounts on May 10, 2024.
Indegene Ltd. (IL) is a leading provider of digital-led commercialization services for the life sciences industry. With over 2 decades of healthcare domain expertise, it offers comprehensive solutions to assist biopharmaceutical, emerging biotech, and medical device companies with drug development, clinical trials, regulatory submissions, pharmacovigilance, complaints management, and sales and marketing.
Indegene Limited boasts a diverse client base. In FY23, this included the 20 largest biopharmaceutical companies globally by revenue (Source: Everest Report). As of December 31, 2023, it had 65 active clients, with a significant portion of its revenue derived from these key relationships. With a team of 5,181 dedicated employees, Indegene Limited is committed to delivering exceptional value to its clients and driving innovation in the life sciences industry.
Indegene Limited Grey Market Premium
| Date | GMP |
| May 2 | ₹242 |
| May 1 | ₹242 |
| April 30 | ₹224 |
| April 29 | ₹169 |
| April 28 | ₹170 |
The last update for Indegene Limited IPO was on May 2, 2024, at 09:54 AM. The GMP is ₹242. The expected listing price of Indegene Limited IPO, with a price band of 452.00, is ₹694 (cap price + today’s GMP). 53.54% is the anticipated percentage gain or loss per share.
